

## **CS Pharmaceuticals announces appointment of Professor Bruce Robinson as Non Executive Director**

London, England, October 24, 2024, CS Pharmaceuticals Ltd. (CSP), a British speciality company focused on first- and best-in-class speciality and ocular therapeutics in China, are pleased to announce the appointment of Professor Bruce Robinson as Non Executive Director.

Professor Bruce Robinson is an endocrinologist. He graduated from the University of Sydney in 1980 and then undertook studies for a Master of Science degree. His further molecular research work was performed at the Brigham and Women's Hospital and the Children's Hospital, Harvard Medical School from 1986–1989 and he was awarded a Doctor of Medicine from the University of Sydney in 1990. Bruce has developed and led the Cancer Genetics Laboratory since 1990 and has supervised over 35 doctoral and master's students working on the genetic basis for tumour formation and gene therapy. He has published over 300 peer-reviewed scientific articles.

Until early 2016, Bruce was Associate Dean (International) in the Faculty of Medicine at the University of Sydney and was Head of the Division of Medicine at the Royal North Shore Hospital from 1998–2006. Bruce also served on the Council of the Endocrine Society of Australia from 2001–2005. He is on the editorial board of the international journals Nature, Clinical Practice and Endocrinology and Thyroid. Bruce has a strong interest in furthering relations between Australia and Asia and he is the Founding Chairman of Hoc Mai, the Australia–Vietnam Medical Foundation, which sponsors and supports medical, nursing, allied health and scientific exchanges between Australia and Vietnam. Bruce was awarded the People's Health Medal by the Vietnamese Government in 2008. Until 2021 he served as the Chair of the Council of National Health and Medical Research Council (NHMRC) and Chair of the Medical Benefits Schedule Taskforce in Australia. Bruce is also the Co-Head of the Cancer Genetics Laboratory at the Kolling Institute at the Royal North Shore Hospital, and the Dean of Medicine 2006–2016 at the University of Sydney.

Bruce is a Fellow of the Australian Institute of Company Directors and Over the last 12 years, Bruce has been a non-executive director in a number of ASX-listed healthcare companies including Cochlear Limited, Mayne Pharma Limited and QBiotics Group.

“We are very honoured to welcome Professor Robinson to the Board”, said Darren Mercer CEO of CSP. “Bruce has had significant experience working and supporting the China expansion with Cochlear Limited which will be a great asset to CSP as we begin to commercialise our products.”

“CSP has an impressive and unique business model with multiple strategies to ensure success. They have some great products in their portfolio and a number of other potential assets under due diligence which could transform the business and make a real difference to patients in China and beyond said Professor Robinson. “I am looking forward to working with the Team at this exciting point in their journey”.

### **About CS Pharmaceuticals**

CS Pharmaceuticals (CSP) is a British multinational company focused on licensing Chinese commercialisation rights to Western speciality and ophthalmology medicines. The company, with its headquarters in London and offices in Beijing and Shanghai, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CS Pharmaceuticals is rapidly becoming a 'go-to' trusted licensing partner, expanding its portfolio of innovative speciality and ophthalmology assets while making business easier for companies wishing to develop and commercialise their products in China.

[www.cspharmaceuticals.com](http://www.cspharmaceuticals.com)

### **Contacts**

CS Pharmaceuticals  
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691

